nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Oedema—Irinotecan—colon cancer	0.00128	0.00128	CcSEcCtD
Methylphenidate—Chest pain—Fluorouracil—colon cancer	0.00128	0.00128	CcSEcCtD
Methylphenidate—Myalgia—Fluorouracil—colon cancer	0.00128	0.00128	CcSEcCtD
Methylphenidate—Infection—Irinotecan—colon cancer	0.00127	0.00127	CcSEcCtD
Methylphenidate—Hyperhidrosis—Vincristine—colon cancer	0.00127	0.00127	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Capecitabine—colon cancer	0.00127	0.00127	CcSEcCtD
Methylphenidate—Epistaxis—Capecitabine—colon cancer	0.00126	0.00126	CcSEcCtD
Methylphenidate—Discomfort—Fluorouracil—colon cancer	0.00126	0.00126	CcSEcCtD
Methylphenidate—Shock—Irinotecan—colon cancer	0.00126	0.00126	CcSEcCtD
Methylphenidate—Nervous system disorder—Irinotecan—colon cancer	0.00125	0.00125	CcSEcCtD
Methylphenidate—Thrombocytopenia—Irinotecan—colon cancer	0.00125	0.00125	CcSEcCtD
Methylphenidate—Anorexia—Vincristine—colon cancer	0.00125	0.00125	CcSEcCtD
Methylphenidate—Irritability—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Hyperhidrosis—Irinotecan—colon cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Confusional state—Fluorouracil—colon cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Mood swings—Methotrexate—colon cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Bradycardia—Capecitabine—colon cancer	0.00122	0.00122	CcSEcCtD
Methylphenidate—Anaphylactic shock—Fluorouracil—colon cancer	0.00122	0.00122	CcSEcCtD
Methylphenidate—Oedema—Fluorouracil—colon cancer	0.00122	0.00122	CcSEcCtD
Methylphenidate—Anorexia—Irinotecan—colon cancer	0.00122	0.00122	CcSEcCtD
Methylphenidate—Infection—Fluorouracil—colon cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Haemoglobin—Capecitabine—colon cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Rhinitis—Capecitabine—colon cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Haemorrhage—Capecitabine—colon cancer	0.0012	0.0012	CcSEcCtD
Methylphenidate—Nervous system disorder—Fluorouracil—colon cancer	0.0012	0.0012	CcSEcCtD
Methylphenidate—Thrombocytopenia—Fluorouracil—colon cancer	0.0012	0.0012	CcSEcCtD
Methylphenidate—Liver function test abnormal—Methotrexate—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Vincristine—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Pharyngitis—Capecitabine—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Tachycardia—Fluorouracil—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Urinary tract disorder—Capecitabine—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Insomnia—Vincristine—colon cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Connective tissue disorder—Capecitabine—colon cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Urethral disorder—Capecitabine—colon cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Paraesthesia—Vincristine—colon cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Breast disorder—Methotrexate—colon cancer	0.00117	0.00117	CcSEcCtD
Methylphenidate—Anorexia—Fluorouracil—colon cancer	0.00117	0.00117	CcSEcCtD
Methylphenidate—Visual impairment—Capecitabine—colon cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Insomnia—Irinotecan—colon cancer	0.00115	0.00115	CcSEcCtD
Methylphenidate—Paraesthesia—Irinotecan—colon cancer	0.00115	0.00115	CcSEcCtD
Methylphenidate—Decreased appetite—Vincristine—colon cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Dyspnoea—Irinotecan—colon cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Erythema multiforme—Capecitabine—colon cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Somnolence—Irinotecan—colon cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Vincristine—colon cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Fatigue—Vincristine—colon cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Eye disorder—Capecitabine—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Dyspepsia—Irinotecan—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Pain—Vincristine—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Constipation—Vincristine—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Asthma—Methotrexate—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Cardiac disorder—Capecitabine—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Flushing—Capecitabine—colon cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Decreased appetite—Irinotecan—colon cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Insomnia—Fluorouracil—colon cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Irinotecan—colon cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Fatigue—Irinotecan—colon cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Paraesthesia—Fluorouracil—colon cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Pancreatitis—Methotrexate—colon cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Pain—Irinotecan—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Constipation—Irinotecan—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Angiopathy—Capecitabine—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Dyspnoea—Fluorouracil—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Somnolence—Fluorouracil—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Immune system disorder—Capecitabine—colon cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Mediastinal disorder—Capecitabine—colon cancer	0.00108	0.00108	CcSEcCtD
Methylphenidate—Chills—Capecitabine—colon cancer	0.00108	0.00108	CcSEcCtD
Methylphenidate—Dyspepsia—Fluorouracil—colon cancer	0.00108	0.00108	CcSEcCtD
Methylphenidate—Arrhythmia—Capecitabine—colon cancer	0.00107	0.00107	CcSEcCtD
Methylphenidate—Abdominal discomfort—Methotrexate—colon cancer	0.00107	0.00107	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Vincristine—colon cancer	0.00107	0.00107	CcSEcCtD
Methylphenidate—Decreased appetite—Fluorouracil—colon cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Alopecia—Capecitabine—colon cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Pancytopenia—Methotrexate—colon cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Mental disorder—Capecitabine—colon cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Feeling abnormal—Irinotecan—colon cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Erythema—Capecitabine—colon cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Malnutrition—Capecitabine—colon cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Pain—Fluorouracil—colon cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Irinotecan—colon cancer	0.00104	0.00104	CcSEcCtD
Methylphenidate—Upper respiratory tract infection—Methotrexate—colon cancer	0.00104	0.00104	CcSEcCtD
Methylphenidate—Abdominal pain—Vincristine—colon cancer	0.00104	0.00104	CcSEcCtD
Methylphenidate—Body temperature increased—Vincristine—colon cancer	0.00104	0.00104	CcSEcCtD
Methylphenidate—Erectile dysfunction—Methotrexate—colon cancer	0.00103	0.00103	CcSEcCtD
Methylphenidate—Photosensitivity reaction—Methotrexate—colon cancer	0.00102	0.00102	CcSEcCtD
Methylphenidate—Back pain—Capecitabine—colon cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Body temperature increased—Irinotecan—colon cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Abdominal pain—Irinotecan—colon cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Feeling abnormal—Fluorouracil—colon cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Muscle spasms—Capecitabine—colon cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Pneumonia—Methotrexate—colon cancer	0.001	0.001	CcSEcCtD
Methylphenidate—Infestation—Methotrexate—colon cancer	0.000997	0.000997	CcSEcCtD
Methylphenidate—Infestation NOS—Methotrexate—colon cancer	0.000997	0.000997	CcSEcCtD
Methylphenidate—Drowsiness—Methotrexate—colon cancer	0.000997	0.000997	CcSEcCtD
Methylphenidate—Depression—Methotrexate—colon cancer	0.000994	0.000994	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000988	0.000988	CcSEcCtD
Methylphenidate—Vision blurred—Capecitabine—colon cancer	0.000986	0.000986	CcSEcCtD
Methylphenidate—Tremor—Capecitabine—colon cancer	0.000981	0.000981	CcSEcCtD
Methylphenidate—Ill-defined disorder—Capecitabine—colon cancer	0.000971	0.000971	CcSEcCtD
Methylphenidate—Urticaria—Fluorouracil—colon cancer	0.000971	0.000971	CcSEcCtD
Methylphenidate—Conjunctivitis—Methotrexate—colon cancer	0.000969	0.000969	CcSEcCtD
Methylphenidate—Anaemia—Capecitabine—colon cancer	0.000967	0.000967	CcSEcCtD
Methylphenidate—Body temperature increased—Fluorouracil—colon cancer	0.000966	0.000966	CcSEcCtD
Methylphenidate—Hypersensitivity—Vincristine—colon cancer	0.000966	0.000966	CcSEcCtD
Methylphenidate—Sweating—Methotrexate—colon cancer	0.000956	0.000956	CcSEcCtD
Methylphenidate—Haematuria—Methotrexate—colon cancer	0.000951	0.000951	CcSEcCtD
Methylphenidate—Malaise—Capecitabine—colon cancer	0.000944	0.000944	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Methotrexate—colon cancer	0.000943	0.000943	CcSEcCtD
Methylphenidate—Epistaxis—Methotrexate—colon cancer	0.00094	0.00094	CcSEcCtD
Methylphenidate—Vertigo—Capecitabine—colon cancer	0.00094	0.00094	CcSEcCtD
Methylphenidate—Hypersensitivity—Irinotecan—colon cancer	0.00094	0.00094	CcSEcCtD
Methylphenidate—Asthenia—Vincristine—colon cancer	0.00094	0.00094	CcSEcCtD
Methylphenidate—Syncope—Capecitabine—colon cancer	0.000939	0.000939	CcSEcCtD
Methylphenidate—Leukopenia—Capecitabine—colon cancer	0.000937	0.000937	CcSEcCtD
Methylphenidate—Palpitations—Capecitabine—colon cancer	0.000925	0.000925	CcSEcCtD
Methylphenidate—Loss of consciousness—Capecitabine—colon cancer	0.00092	0.00092	CcSEcCtD
Methylphenidate—Asthenia—Irinotecan—colon cancer	0.000916	0.000916	CcSEcCtD
Methylphenidate—Cough—Capecitabine—colon cancer	0.000913	0.000913	CcSEcCtD
Methylphenidate—Hypertension—Capecitabine—colon cancer	0.000904	0.000904	CcSEcCtD
Methylphenidate—Hypersensitivity—Fluorouracil—colon cancer	0.000901	0.000901	CcSEcCtD
Methylphenidate—Haemoglobin—Methotrexate—colon cancer	0.0009	0.0009	CcSEcCtD
Methylphenidate—Diarrhoea—Vincristine—colon cancer	0.000897	0.000897	CcSEcCtD
Methylphenidate—Haemorrhage—Methotrexate—colon cancer	0.000895	0.000895	CcSEcCtD
Methylphenidate—Myalgia—Capecitabine—colon cancer	0.000891	0.000891	CcSEcCtD
Methylphenidate—Chest pain—Capecitabine—colon cancer	0.000891	0.000891	CcSEcCtD
Methylphenidate—Arthralgia—Capecitabine—colon cancer	0.000891	0.000891	CcSEcCtD
Methylphenidate—Pharyngitis—Methotrexate—colon cancer	0.000888	0.000888	CcSEcCtD
Methylphenidate—Anxiety—Capecitabine—colon cancer	0.000888	0.000888	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000885	0.000885	CcSEcCtD
Methylphenidate—Urinary tract disorder—Methotrexate—colon cancer	0.000884	0.000884	CcSEcCtD
Methylphenidate—Discomfort—Capecitabine—colon cancer	0.00088	0.00088	CcSEcCtD
Methylphenidate—Urethral disorder—Methotrexate—colon cancer	0.000877	0.000877	CcSEcCtD
Methylphenidate—Diarrhoea—Irinotecan—colon cancer	0.000873	0.000873	CcSEcCtD
Methylphenidate—Dry mouth—Capecitabine—colon cancer	0.000871	0.000871	CcSEcCtD
Methylphenidate—Dizziness—Vincristine—colon cancer	0.000867	0.000867	CcSEcCtD
Methylphenidate—Pruritus—Fluorouracil—colon cancer	0.000865	0.000865	CcSEcCtD
Methylphenidate—Visual impairment—Methotrexate—colon cancer	0.000863	0.000863	CcSEcCtD
Methylphenidate—Confusional state—Capecitabine—colon cancer	0.000861	0.000861	CcSEcCtD
Methylphenidate—Oedema—Capecitabine—colon cancer	0.000854	0.000854	CcSEcCtD
Methylphenidate—Infection—Capecitabine—colon cancer	0.000849	0.000849	CcSEcCtD
Methylphenidate—Erythema multiforme—Methotrexate—colon cancer	0.000846	0.000846	CcSEcCtD
Methylphenidate—Dizziness—Irinotecan—colon cancer	0.000844	0.000844	CcSEcCtD
Methylphenidate—Shock—Capecitabine—colon cancer	0.00084	0.00084	CcSEcCtD
Methylphenidate—Nervous system disorder—Capecitabine—colon cancer	0.000838	0.000838	CcSEcCtD
Methylphenidate—Eye disorder—Methotrexate—colon cancer	0.000836	0.000836	CcSEcCtD
Methylphenidate—Diarrhoea—Fluorouracil—colon cancer	0.000836	0.000836	CcSEcCtD
Methylphenidate—Thrombocytopenia—Capecitabine—colon cancer	0.000836	0.000836	CcSEcCtD
Methylphenidate—Tachycardia—Capecitabine—colon cancer	0.000834	0.000834	CcSEcCtD
Methylphenidate—Vomiting—Vincristine—colon cancer	0.000833	0.000833	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—colon cancer	0.000831	0.000831	CcSEcCtD
Methylphenidate—Skin disorder—Capecitabine—colon cancer	0.00083	0.00083	CcSEcCtD
Methylphenidate—Rash—Vincristine—colon cancer	0.000826	0.000826	CcSEcCtD
Methylphenidate—Hyperhidrosis—Capecitabine—colon cancer	0.000826	0.000826	CcSEcCtD
Methylphenidate—Dermatitis—Vincristine—colon cancer	0.000826	0.000826	CcSEcCtD
Methylphenidate—Headache—Vincristine—colon cancer	0.000821	0.000821	CcSEcCtD
Methylphenidate—Anorexia—Capecitabine—colon cancer	0.000814	0.000814	CcSEcCtD
Methylphenidate—Angiopathy—Methotrexate—colon cancer	0.000812	0.000812	CcSEcCtD
Methylphenidate—Vomiting—Irinotecan—colon cancer	0.000811	0.000811	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—colon cancer	0.000808	0.000808	CcSEcCtD
Methylphenidate—Dizziness—Fluorouracil—colon cancer	0.000808	0.000808	CcSEcCtD
Methylphenidate—Mediastinal disorder—Methotrexate—colon cancer	0.000807	0.000807	CcSEcCtD
Methylphenidate—Rash—Irinotecan—colon cancer	0.000805	0.000805	CcSEcCtD
Methylphenidate—Dermatitis—Irinotecan—colon cancer	0.000804	0.000804	CcSEcCtD
Methylphenidate—Chills—Methotrexate—colon cancer	0.000803	0.000803	CcSEcCtD
Methylphenidate—Headache—Irinotecan—colon cancer	0.0008	0.0008	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—colon cancer	0.000791	0.000791	CcSEcCtD
Methylphenidate—Mental disorder—Methotrexate—colon cancer	0.000784	0.000784	CcSEcCtD
Methylphenidate—Erythema—Methotrexate—colon cancer	0.000779	0.000779	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—colon cancer	0.000779	0.000779	CcSEcCtD
Methylphenidate—Nausea—Vincristine—colon cancer	0.000778	0.000778	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000778	0.000778	CcSEcCtD
Methylphenidate—Vomiting—Fluorouracil—colon cancer	0.000777	0.000777	CcSEcCtD
Methylphenidate—Insomnia—Capecitabine—colon cancer	0.000773	0.000773	CcSEcCtD
Methylphenidate—Rash—Fluorouracil—colon cancer	0.000771	0.000771	CcSEcCtD
Methylphenidate—Dermatitis—Fluorouracil—colon cancer	0.00077	0.00077	CcSEcCtD
Methylphenidate—Paraesthesia—Capecitabine—colon cancer	0.000767	0.000767	CcSEcCtD
Methylphenidate—Headache—Fluorouracil—colon cancer	0.000766	0.000766	CcSEcCtD
Methylphenidate—Dyspnoea—Capecitabine—colon cancer	0.000762	0.000762	CcSEcCtD
Methylphenidate—Nausea—Irinotecan—colon cancer	0.000758	0.000758	CcSEcCtD
Methylphenidate—Back pain—Methotrexate—colon cancer	0.000754	0.000754	CcSEcCtD
Methylphenidate—Dyspepsia—Capecitabine—colon cancer	0.000752	0.000752	CcSEcCtD
Methylphenidate—Decreased appetite—Capecitabine—colon cancer	0.000743	0.000743	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Capecitabine—colon cancer	0.000737	0.000737	CcSEcCtD
Methylphenidate—Fatigue—Capecitabine—colon cancer	0.000736	0.000736	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—colon cancer	0.000734	0.000734	CcSEcCtD
Methylphenidate—Pain—Capecitabine—colon cancer	0.00073	0.00073	CcSEcCtD
Methylphenidate—Constipation—Capecitabine—colon cancer	0.00073	0.00073	CcSEcCtD
Methylphenidate—Nausea—Fluorouracil—colon cancer	0.000726	0.000726	CcSEcCtD
Methylphenidate—Ill-defined disorder—Methotrexate—colon cancer	0.000723	0.000723	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—colon cancer	0.00072	0.00072	CcSEcCtD
Methylphenidate—Feeling abnormal—Capecitabine—colon cancer	0.000704	0.000704	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—colon cancer	0.000703	0.000703	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—colon cancer	0.0007	0.0007	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Capecitabine—colon cancer	0.000698	0.000698	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—colon cancer	0.000697	0.000697	CcSEcCtD
Methylphenidate—Cough—Methotrexate—colon cancer	0.00068	0.00068	CcSEcCtD
Methylphenidate—Urticaria—Capecitabine—colon cancer	0.000679	0.000679	CcSEcCtD
Methylphenidate—Body temperature increased—Capecitabine—colon cancer	0.000675	0.000675	CcSEcCtD
Methylphenidate—Abdominal pain—Capecitabine—colon cancer	0.000675	0.000675	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—colon cancer	0.000675	0.000675	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—colon cancer	0.000663	0.000663	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—colon cancer	0.000663	0.000663	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—colon cancer	0.000663	0.000663	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000659	0.000659	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—colon cancer	0.000655	0.000655	CcSEcCtD
Methylphenidate—Confusional state—Methotrexate—colon cancer	0.000641	0.000641	CcSEcCtD
Methylphenidate—Anaphylactic shock—Methotrexate—colon cancer	0.000636	0.000636	CcSEcCtD
Methylphenidate—Infection—Methotrexate—colon cancer	0.000632	0.000632	CcSEcCtD
Methylphenidate—Hypersensitivity—Capecitabine—colon cancer	0.000629	0.000629	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—colon cancer	0.000624	0.000624	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—colon cancer	0.000623	0.000623	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—colon cancer	0.000618	0.000618	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—colon cancer	0.000615	0.000615	CcSEcCtD
Methylphenidate—Asthenia—Capecitabine—colon cancer	0.000613	0.000613	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—colon cancer	0.000606	0.000606	CcSEcCtD
Methylphenidate—Pruritus—Capecitabine—colon cancer	0.000604	0.000604	CcSEcCtD
Methylphenidate—Diarrhoea—Capecitabine—colon cancer	0.000584	0.000584	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000579	0.000579	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—colon cancer	0.000575	0.000575	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—colon cancer	0.000571	0.000571	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—colon cancer	0.000567	0.000567	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—colon cancer	0.000565	0.000565	CcSEcCtD
Methylphenidate—Dizziness—Capecitabine—colon cancer	0.000565	0.000565	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—colon cancer	0.00056	0.00056	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—colon cancer	0.000553	0.000553	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—colon cancer	0.000549	0.000549	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—colon cancer	0.000548	0.000548	CcSEcCtD
Methylphenidate—Pain—Methotrexate—colon cancer	0.000544	0.000544	CcSEcCtD
Methylphenidate—Vomiting—Capecitabine—colon cancer	0.000543	0.000543	CcSEcCtD
Methylphenidate—Rash—Capecitabine—colon cancer	0.000539	0.000539	CcSEcCtD
Methylphenidate—Dermatitis—Capecitabine—colon cancer	0.000538	0.000538	CcSEcCtD
Methylphenidate—Headache—Capecitabine—colon cancer	0.000535	0.000535	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—colon cancer	0.000524	0.000524	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Methotrexate—colon cancer	0.00052	0.00052	CcSEcCtD
Methylphenidate—Nausea—Capecitabine—colon cancer	0.000507	0.000507	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—colon cancer	0.000505	0.000505	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—colon cancer	0.000503	0.000503	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—colon cancer	0.000503	0.000503	CcSEcCtD
Methylphenidate—Hypersensitivity—Methotrexate—colon cancer	0.000468	0.000468	CcSEcCtD
Methylphenidate—Asthenia—Methotrexate—colon cancer	0.000456	0.000456	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—colon cancer	0.00045	0.00045	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—colon cancer	0.000435	0.000435	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—colon cancer	0.00042	0.00042	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—colon cancer	0.000404	0.000404	CcSEcCtD
Methylphenidate—Rash—Methotrexate—colon cancer	0.000401	0.000401	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—colon cancer	0.000401	0.000401	CcSEcCtD
Methylphenidate—Headache—Methotrexate—colon cancer	0.000398	0.000398	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—colon cancer	0.000378	0.000378	CcSEcCtD
